Recent advancement in modern genomic tools for adaptation of Lablab purpureus L to biotic and abiotic stresses: present mechanisms and future adaptations

Not AvailableHyacinth bean is an important traditional plant with substantial medicinal value. Being imperative, it is still less explored crop on genomic and transcriptomic scale that has indexed it as an “orphan” crop for its genome revolution. Among different crop legumes such as pigeon pea, chickpea, cowpea, soybean and common bean, hyacinth bean also serves as a significant source of nutrition for both tropical and temperate regions and execute an imperative function in fixing biological nitrogen in agriculture. Nonetheless, the productivity of hyacinth bean is restrained due to environmental and biotic cues. Thus, understanding of the genomic functions and identification of probable genes/proteins for major agronomic traits through transcriptomic approaches has become imperative to improve stress tolerance in hyacinth bean. For understanding the plant stress tolerance mechanisms, the deployment of functional genomics approaches viz., proteomics and metabolomics have become imperious in breeding programs in developing countries. These approaches have been successfully used in other legume crops to create protein reference maps and their exploitation through comparative approaches can greatly enhance the research and understanding of hyacinth bean biological processes to changing environmental conditions. In this review, emerging epigenomics, proteomics, metabolomics and phenomics approaches and their achievements both in model/crop legumes are discussed. Additionally, the review also provides an overview of the applications of advanced proteomics, metabolomics and next-generation sequencing technologies in the discovery of candidate biomarkers for the development of agronomically refined hyacinth bean which may further ensure food and nutritional security under adverse climacteric conditions in developing countries.Not Availabl

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)